Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis

NACompletedINTERVENTIONAL
Enrollment

962

Participants

Timeline

Start Date

July 2, 2012

Primary Completion Date

April 26, 2021

Study Completion Date

April 26, 2021

Conditions
Patients Scheduled for Prostate Biopsy Because of Increased Serum PSA and/or Abnormal Digital Rectal Examination
Interventions
OTHER

urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)

urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.

Trial Locations (10)

21079

Hôpital du Bocage, Dijon

49933

CHU Angers, Angers

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75013

Hôpital Pitié-Salpêtrière,, Paris

75020

Hôpital Tenon, Paris

86000

Hôpital de la Milétrie, Poitiers

Unknown

Centre Hospitalier Alpes Leman, Contamine-sur-Arve

Hôpital Edouard Herriot, Lyon

Centre hospitalier de Thonon les bains, Thonon-les-Bains

Centre Hospitalier de Valence, Valence

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT01632930 - Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis | Biotech Hunter | Biotech Hunter